Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Differential diagnosis of suspected multiple sclerosis: an updated consensus approach.
Solomon AJ, Arrambide G, Brownlee WJ, Flanagan EP, Amato MP, Amezcua L, Banwell BL, Barkhof F, Corboy JR, Correale J, Fujihara K, Graves J, Harnegie MP, Hemmer B, Lechner-Scott J, Marrie RA, Newsome SD, Rocca MA, Royal W 3rd, Waubant EL, Yamout B, Cohen JA. Solomon AJ, et al. Among authors: amezcua l. Lancet Neurol. 2023 Aug;22(8):750-768. doi: 10.1016/S1474-4422(23)00148-5. Lancet Neurol. 2023. PMID: 37479377 Review.
Vitamin D levels in Hispanics with multiple sclerosis.
Amezcua L, Chung RH, Conti DV, Langer-Gould AM. Amezcua L, et al. J Neurol. 2012 Dec;259(12):2565-70. doi: 10.1007/s00415-012-6537-z. Epub 2012 May 16. J Neurol. 2012. PMID: 22588255
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Cree BAC, Cutter G, Wolinsky JS, Freedman MS, Comi G, Giovannoni G, Hartung HP, Arnold D, Kuhle J, Block V, Munschauer FE, Sedel F, Lublin FD; SPI2 investigative teams. Cree BAC, et al. Lancet Neurol. 2020 Dec;19(12):988-997. doi: 10.1016/S1474-4422(20)30347-1. Epub 2020 Oct 23. Lancet Neurol. 2020. PMID: 33222767 Clinical Trial.
Consensus Curriculum for Fellowship Training in Multiple Sclerosis and Neuroimmunology.
Hua LH, Obeidat AZ, Amezcua L, Cohen JA, Costello K, Dunn J, Gelfand JM, Goldman MD, Hopkins S, Jeffery D, Krieger S, Newsome SD, Shah S, Sicotte NL, Yadav V, Longbrake EE. Hua LH, et al. Among authors: amezcua l. Neurol Clin Pract. 2021 Aug;11(4):352-357. doi: 10.1212/CPJ.0000000000001040. Neurol Clin Pract. 2021. PMID: 34484933 Free PMC article.
MOG Antibody-Associated Disease and Thymic Hyperplasia: From the National Multiple Sclerosis Society Case Conference Proceedings.
Hurtubise B, Frohman EM, Galetta S, Balcer LJ, Frohman TC, Lisak RP, Newsome SD, Graves JS, Zamvil SS, Amezcua L. Hurtubise B, et al. Among authors: amezcua l. Neurol Neuroimmunol Neuroinflamm. 2022 Dec 14;10(2):e200077. doi: 10.1212/NXI.0000000000200077. Print 2023 Mar. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 36517233 Free PMC article.
Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial.
Corboy JR, Fox RJ, Kister I, Cutter GR, Morgan CJ, Seale R, Engebretson E, Gustafson T, Miller AE; DISCOMS investigators. Corboy JR, et al. Lancet Neurol. 2023 Jul;22(7):568-577. doi: 10.1016/S1474-4422(23)00154-0. Lancet Neurol. 2023. PMID: 37353277 Clinical Trial.
Enhancing diversity of clinical trial populations in multiple sclerosis.
Marrie RA, Chataway J, Bierer BE, Finlayson M, Martinez-Lapiscina EH, Panagoulias J, Sormani MP, Williams MJ, Amezcua L. Marrie RA, et al. Among authors: amezcua l. Mult Scler. 2023 Aug;29(9):1174-1185. doi: 10.1177/13524585231189677. Mult Scler. 2023. PMID: 37555490 Free PMC article. Review.
72 results